^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CT0180

    i
    Other names: CT0180, GPC3 CAR-T, glypican-3 (GPC3) directed CAR-T cell therapy, CSG-GPC3, Glypican 3 chimeric antigen receptor T cell therapy, KJgpc3-001, CAR-GPC3 T Cells, chimeric antigen receptor T cells targeting glypican-3, GPC3-CAR/CSG-GPC3, GPC3-CAR-T cell therapy, anti-GPC3 CAR T
    Associations

    News

    Trials
    Company:
    CARsgen
    Drug class:
    GPC-3-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. (PubMed, EClinicalMedicine)
    CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8 T-cell infiltration into the cancer microenvironment...These results need to be confirmed in a robust clinical trial. This study was funded by CARsgen Therapeutics Co., Ltd.
    P1 data • Journal • CAR T-Cell Therapy • Metastases
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3) • TCF3 (Transcription Factor 3) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    GPC3 expression • GPC3 positive
    |
    CT017 • CT0180
    over1year
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Recruiting, Zhejiang University | Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • GPC3 (Glypican 3)
    |
    cyclophosphamide • CT0180
    over1year
    Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma. (ASCO 2023)
    Lymphodepletion regimen comprised fludarabine 25 mg/m2 and cyclophosphamide 300 mg/m2 daily for 3 days...Grade 1 cytokine release syndrome was observed in 6 patients; tocilizumab was given in one patient and no glucocorticoids were used... CT0180 demonstrated manageable safety profile and promising antitumor potential. Further exploration of CT0180 in HCC is needed. Clinical trial information: NCT04756648.
    Clinical • P1 data • Metastases
    |
    IL6 (Interleukin 6) • GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • CT0180
    almost2years
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Recruiting, Zhejiang University | Trial primary completion date: Apr 2022 --> Mar 2023
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • GPC3 (Glypican 3)
    |
    cyclophosphamide • CT0180
    over2years
    Chimeric Antigen Receptor T Cells Targeting Glypican-3 (clinicaltrials.gov)
    P1, N=9, Completed, CARsgen Therapeutics Co., Ltd. | Recruiting --> Completed | N=15 --> 9 | Trial completion date: May 2024 --> Dec 2021
    Trial completion • Enrollment change • Trial completion date • CAR T-Cell Therapy
    |
    GPC3 (Glypican 3)
    |
    CT0180
    3years
    CISLD-4: 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 (clinicaltrials.gov)
    P1, N=6, Completed, Zhejiang University | Recruiting --> Completed | N=36 --> 6 | Trial completion date: Jun 2022 --> Dec 2020 | Trial primary completion date: Jun 2021 --> Dec 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    GPC3 (Glypican 3)
    |
    CT0180
    3years
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • GPC3 (Glypican 3)
    |
    CT0180
    over3years
    [VIRTUAL] Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma. (ASCO 2021)
    Among them, 1 patient received half dose of sorafenib and 3 patients received half dose of regorafenib along with cell infusion...Patients recovered from CRS after tocilizumab therapy with corticosteroid (4 patients) or without... Our study is the first to report that 4G-CAR-GPC3 T cell therapy in combination with TKIs has a manageable safety profile while demonstrating potential antitumor activity for heavily pretreated advanced HCC patients; however, CRS should be diligently managed.
    P1 data • CAR T-Cell Therapy
    |
    GPC3 (Glypican 3)
    |
    sorafenib • Stivarga (regorafenib) • Actemra IV (tocilizumab) • CT0180
    over3years
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Zhejiang University
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • GPC3 (Glypican 3)
    |
    CT0180
    4years
    Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (clinicaltrials.gov)
    P=N/A, N=18, Active, not recruiting, Kang YU | Recruiting --> Active, not recruiting | N=48 --> 18 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2019 --> Dec 2020
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18) • CD19 (CD19 Molecule) • GPC3 (Glypican 3)
    |
    CD19 positive • GPC3 positive
    |
    fludarabine IV • satricabtagene autoleucel (CT041) • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)